|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we investigate a unique variant of familial hypercalcemia, unrelated to multiple endocrine neoplasia and hyperparathyroidism-jaw tumor syndromes, with hypercalcemia due to a point mutation in the intracellular part of the calcium receptor (CaR) gene.
|
12161540 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mean value of CAR expression was significantly lower in 22 Grade IV tumors as compared to the values for 6 Grade II (p = 0.01) and 6 Grade III (p = 0.01) tumors.
|
12516090 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Intratumoral injection of the Ad.Lp-CD-IRES-E1A(MRGD) vector following the intraperitoneal injection of 5FC into xenotransplanted human breast cancer cell lines which have low expression level of CAR led to greater degree of tumor regression in vivo than did the intratumoral injection of control adenoviral vectors not so modified.
|
16179927 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive transfer of a patient's own T cells, genetically modified ex vivo through the introduction of a gene encoding a chimeric antigen receptor (CAR) targeted to a tumor-associated antigen, is a novel approach to the treatment of ovarian cancer.
|
20628030 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we investigated whether the tumor trafficking of activated T cells (ATCs) bearing a chimeric antigen receptor specific for the tumor antigen GD2 (GD2-CAR) could be enhanced by forced coexpression of the chemokine receptor CCR2b, as this receptor directs migration toward CCL2, a chemokine produced by many tumors, including neuroblastoma.
|
20842059 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a mouse model of two-step liver tumorigenesis, in which tumor growth was initiated by diethyl nitrosamine (DEN) and promoted by chronic treatment with PB, we previously demonstrated that tumors developed only in the presence of CAR.
|
21424122 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells bearing a functional chemokine receptor can overcome the inadequate tumor localization that limits conventional CAR targeting strategies and can significantly improve antitumor efficacy in vivo.
|
21610146 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The insertion of peptides into fiber proved more effective for targeting tumor cell types expressing low levels of CAR receptor, as this strategy can partially compensate for the very low infectivity of wild-type adenovirus in those cells.
|
22595794 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this article, we review the use of NKG2D as a basis for CAR targeting of tumors.
|
24667963 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Extending the use of CAR therapies to cancers other than B-cell malignancies will require selective tumor targeting with minimal or acceptable "on-target, off-tumor" effects.
|
24667964 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive transfer of T lymphocytes expressing a CD19-specific chimeric antigen receptor (CAR.CD19) induces complete tumor regression in patients with lymphoid malignancies.
|
24782509 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, male transgenic mice expressing human CAR and PXR were used to detect possible differences between wild-type (WT) and humanized mice in their response to CAR activation in a tumor initiation/promotion experiment with a single injection of the tumor initiator N-nitrosodiethylamine preceding chronic PB treatment for 10 months.
|
24863967 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Human T cells expressing CAR targeting mesothelin or fibroblast activation protein and containing CD3ζ and 4-1BB cytoplasmic domains were intravenously injected into immunodeficient mice bearing large, established human mesothelin-expressing flank tumors.
|
24919573 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on these studies, it was demonstrated that the liver tumors were mediated by a mode of action (MoA) involving nuclear receptors (NRs) through the following key events: (1) CAR and PPAR-α receptor activation, (2) increased hepatocellular proliferation, eventually leading to (3) hepatocellular tumors.
|
25092647 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the CAR exPBNK-treated mice had significantly extended survival time (P < 0.001) and reduced tumor size, compared with those of the untreated and the CAR(-) exPBNK-treated mice (P < 0.05).
|
25492700 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Researchers increased the effectiveness of CAR T-cell therapy in solid tumors by injecting the cells near the tumors.
|
25583818 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because CAR-T cells recognize tumor cells independent of their expression of human leukocyte antigen (HLA) molecules, tumors that escape conventional T cells by downregulating HLA and/or mutating components of the antigen processing machinery can be eliminated.
|
25621840 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These responses are strictly limited and are tightly linked, since β-catenin is activated in nearly all of the CAR-dependent tumours generated by the tumour promoter phenobarbital.
|
25661872 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HER2-CAR T cells were detected at tumor sites of two of two patients examined.
|
25800760 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cells were incubated with Raji cells and the LDH test was performed to detect the cytotoxic effect of CAR-T cells; the tumor volume and survival rate were measured to observe its inhibitory effect on B cell lymphoma in nude mice.
|
26195067 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Intratumoral injection of AxdAdB3-F/RGD into CAR-negative prostate cancer cell xenografts in nude mice inhibited tumor growth.
|
26799485 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To date, dozens of different CAR-T cells have been evaluated in clinical trials to treat tumors; this necessitates the establishment of guidelines for the production and application of CAR-T cells.
|
26965523 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IP CAR-Ts provided protection against tumor growth at distant subcutaneous (SC) sites in association with increases in serum IFNγ levels.
|
27080226 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrate that both switch formats can be readily optimized to redirect CAR-T cells (specific for the corresponding FITC or PNE) to Her2-expressing tumor cells, and afford dose-titratable activation of CAR-T cells ex vivo and complete clearance of the tumor in rodent xenograft models.
|
27145250 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BiTEs were secreted from the transferred T cells and enabled both the transferred and bystander T cells to specifically recognize CD19(+) cell lines, with increased tumor killing ability, prolonged functional persistence, increased cytokine production and potent proliferation compared with the CAR-T cells.
|
27258611 |
2016 |